205 related articles for article (PubMed ID: 31342847)
1. Neuropathic pain and Kv7 voltage-gated potassium channels: The potential role of Kv7 activators in the treatment of neuropathic pain.
Abd-Elsayed A; Jackson M; Gu SL; Fiala K; Gu J
Mol Pain; 2019; 15():1744806919864256. PubMed ID: 31342847
[TBL] [Abstract][Full Text] [Related]
2. Activation of K
Djouhri L; Malki MI; Zeidan A; Nagi K; Smith T
J Drug Target; 2019 Dec; 27(10):1118-1126. PubMed ID: 30995134
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
Zhang F; Liu S; Jin L; Tang L; Zhao X; Yang T; Wang Y; Huo B; Liu R; Li H
Pharmacology; 2020; 105(7-8):471-476. PubMed ID: 32062659
[TBL] [Abstract][Full Text] [Related]
4. Possible involvement of nitric oxide modulatory mechanism in the protective effect of retigabine against spinal nerve ligation-induced neuropathic pain.
Pottabathini R; Kumar A; Bhatnagar A; Garg S
Cell Mol Neurobiol; 2015 Jan; 35(1):137-46. PubMed ID: 25182225
[TBL] [Abstract][Full Text] [Related]
5. Retigabine: chemical synthesis to clinical application.
Blackburn-Munro G; Dalby-Brown W; Mirza NR; Mikkelsen JD; Blackburn-Munro RE
CNS Drug Rev; 2005; 11(1):1-20. PubMed ID: 15867950
[TBL] [Abstract][Full Text] [Related]
6. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Dost R; Rostock A; Rundfeldt C
Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
[TBL] [Abstract][Full Text] [Related]
7. Orofacial neuropathic pain induced by oxaliplatin: downregulation of KCNQ2 channels in V2 trigeminal ganglion neurons and treatment by the KCNQ2 channel potentiator retigabine.
Ling J; Erol F; Viatchenko-Karpinski V; Kanda H; Gu JG
Mol Pain; 2017; 13():1744806917724715. PubMed ID: 28741430
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in Kv7 channel function in the cerebral and coronary circulation.
Lee S; Yang Y; Tanner MA; Li M; Hill MA
Microcirculation; 2015 Feb; 22(2):109-121. PubMed ID: 25476662
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
Miceli F; Soldovieri MV; Martire M; Taglialatela M
Curr Opin Pharmacol; 2008 Feb; 8(1):65-74. PubMed ID: 18061539
[TBL] [Abstract][Full Text] [Related]
10. Effects of natural and synthetic isothiocyanate-based H
Di Cesare Mannelli L; Lucarini E; Micheli L; Mosca I; Ambrosino P; Soldovieri MV; Martelli A; Testai L; Taglialatela M; Calderone V; Ghelardini C
Neuropharmacology; 2017 Jul; 121():49-59. PubMed ID: 28431970
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain.
Sakai A; Saitow F; Maruyama M; Miyake N; Miyake K; Shimada T; Okada T; Suzuki H
Nat Commun; 2017 Jul; 8():16079. PubMed ID: 28677679
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
13. KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia.
Abd-Elsayed AA; Ikeda R; Jia Z; Ling J; Zuo X; Li M; Gu JG
Mol Pain; 2015 Jul; 11():45. PubMed ID: 26227020
[TBL] [Abstract][Full Text] [Related]
14. Expression and motor functional roles of voltage-dependent type 7 K(+) channels in the human taenia coli.
Adduci A; Martire M; Taglialatela M; Arena V; Rizzo G; Coco C; Currò D
Eur J Pharmacol; 2013 Dec; 721(1-3):12-20. PubMed ID: 24120659
[TBL] [Abstract][Full Text] [Related]
15. Voltage-gated Na+ channels in neuropathic pain.
Hargus NJ; Patel MK
Expert Opin Investig Drugs; 2007 May; 16(5):635-46. PubMed ID: 17461737
[TBL] [Abstract][Full Text] [Related]
16. XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits.
Greene DL; Kang S; Hoshi N
J Pharmacol Exp Ther; 2017 Jul; 362(1):177-185. PubMed ID: 28483800
[TBL] [Abstract][Full Text] [Related]
17. Effect of glucoraphanin and sulforaphane against chemotherapy-induced neuropathic pain: Kv7 potassium channels modulation by H
Lucarini E; Micheli L; Trallori E; Citi V; Martelli A; Testai L; De Nicola GR; Iori R; Calderone V; Ghelardini C; Di Cesare Mannelli L
Phytother Res; 2018 Nov; 32(11):2226-2234. PubMed ID: 30069944
[TBL] [Abstract][Full Text] [Related]
18. One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.
Jepps TA; Olesen SP; Greenwood IA
Br J Pharmacol; 2013 Jan; 168(1):19-27. PubMed ID: 22880633
[TBL] [Abstract][Full Text] [Related]
19. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
20. Targeting 5-HT
Vizcarra VS; Barber KR; Franca-Solomon G; Majuta L; Smith A; Langlais PR; Largent-Milnes TM; Vanderah TW; Riegel AC
Neurosci Lett; 2022 Oct; 789():136864. PubMed ID: 36063980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
